Yamuna Devi Bakthavatchalam
Overview
Explore the profile of Yamuna Devi Bakthavatchalam including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
69
Citations
424
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Veeraraghavan B, Shin E, Bakthavatchalam Y, Manesh A, Dubey D, Tascini C, et al.
Antimicrob Agents Chemother
. 2025 Mar;
:e0162724.
PMID: 40035550
In the ATTACK Phase 3 trial examining the efficacy of sulbactam (SUL)/durlobactam (DUR) to treat primarily complex (ABC) infections, imipenem (IPM)/cilastatin was added as a common therapy to both the...
2.
Karthik M, Kacha S, Rajendran S, Bakthavatchalam Y, Lal B, Walia K, et al.
Infect Genet Evol
. 2024 Dec;
126:105701.
PMID: 39653106
Pseudomonas aeruginosa exhibits significant antibiotic resistance facilitated by both intrinsic and acquired mechanisms, prominently through Pseudomonas-derived cephalosporinase (PDC), serine Ambler class C β-lactamases encoded by the AmpC. AmpC, involved in...
3.
Bakthavatchalam Y, Behera B, Shah A, Mathur P, Ray R, Fomda B, et al.
Microbiol Spectr
. 2024 Nov;
13(1):e0049724.
PMID: 39560385
Importance: Metallo-β-lactamases are therapeutically challenging due to the limited treatment options. Against such isolates, currently approved newer β-lactam/β-lactamase inhibitor combinations are ineffective. In this study, we tested siderophore cephalosporin, cefiderocol,...
4.
Bakthavatchalam Y, Karthik R, Ashok A, Walia K, Ragothaman H, Krishnamoorthy S, et al.
Indian J Med Microbiol
. 2024 Nov;
52:100755.
PMID: 39550069
In the present study, we determine the synergistic activity of ertapenem with cefazolin and flucloxacillin against type A beta-lactamase producing Methicillin susceptible Staphylococcus aureus isolate. In the time kill assay,...
5.
Bakthavatchalam Y, Shankar C, Jeyaraj C, Neeravi A, Mathur P, Nagvekar V, et al.
Diagn Microbiol Infect Dis
. 2024 Oct;
111(1):116561.
PMID: 39432962
Objectives: In vitro activity of β-lactam enhancer/β-lactam combination zidebactam/cefepime was evaluated against carbapenem- and colistin-resistant Klebsiella pneumoniae isolates. Methods: Non duplicate K. pneumoniae (n=185), resistant to colistin as well as...
6.
Bakthavatchalam Y, Manoharan Y, Shankar A, Gunasekaran K, Walia K, Veeraraghavan B
Eur J Clin Microbiol Infect Dis
. 2024 Sep;
43(12):2453-2457.
PMID: 39297907
Stenotrophomonas maltophilia is challenging to treat due to the presence of multiple intrinsic and acquired resistance mechanisms. TMP-SMZ is the standard care of therapy for treating S. maltophilia infections; levofloxavin...
7.
Bakthavatchalam Y, Abdullah F, Srinivasan D, Nithiyanandam S, Neeravi A, Shah P, et al.
Indian J Med Microbiol
. 2024 Aug;
52:100710.
PMID: 39181333
Background: There is a high diversity of beta-lactamases in gram negative pathogens, making them difficult to treat. In the presence of OXA-1 and ampC, PTZ is no longer clinically relevant...
8.
Bakthavatchalam Y, Jennifer L, Abdullah F, Srinivasan D, Adhiya R, Ashok A, et al.
Indian J Med Microbiol
. 2024 Aug;
51:100695.
PMID: 39094970
Introduction: Biapenem has been recently approved by the Drug Controller General of India for the treatment of complicated urinary tract infections (cUTI). However, there are no assessment studies that evaluate...
9.
Joshi P, Joshi S, Periasamy H, Bakthavatchalam Y, Velmurugan A, Veeraraghavan B, et al.
Int J Antimicrob Agents
. 2024 Jun;
64(2):107249.
PMID: 38906486
No abstract available.
10.
Juliet R, Loganathan A, Neeravi A, Bakthavatchalam Y, Veeraraghavan B, Manohar P, et al.
Front Microbiol
. 2024 Jun;
15:1391777.
PMID: 38887719
The emergence of multi-drug resistance in , causing food-borne infections, is a significant issue. With over 2,600 serovars in in sp., it is crucial to identify specific solutions for each...